PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study

SIMPLE SUMMARY: Prostate-specific membrane antigen-direct radioligand therapy is a novel treatment for patients with castration-resistant prostate cancer. Yet, given the mode of action of PSMA-RLT, it is postulated that in early disease prostate cancer settings, e.g. hormone-sensitive, can also bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Banda, Amina, Privé, Bastiaan M., Allach, Youssra, Uijen, Maike J. M., Peters, Steffie M. B., Loeff, Cato C., Gotthardt, Martin, Muselaers, Constantijn H. J., Witjes, J. Alfred, van Oort, Inge M., Sedelaar, J. P. Michiel, Westdorp, Harm, Mehra, Niven, Khreish, Fadi, Ezziddin, Samer, Sabet, Amir, Kreissl, Michael C., Winkens, Thomas, Seifert, Philipp, Janssen, Marcel J. R., van Gemert, Willemijn A. M., Nagarajah, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818570/
https://www.ncbi.nlm.nih.gov/pubmed/36612293
http://dx.doi.org/10.3390/cancers15010297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818570/
https://www.ncbi.nlm.nih.gov/pubmed/36612293
http://dx.doi.org/10.3390/cancers15010297

Ejemplares similares